The ‘puzzle’ of noncompliance: Skipped radiation and lives lost

Chu and colleagues report that as many as 35% of high-risk patients with breast cancer in the United States who have N2 to N3 locally advanced disease do not receive a potentially curative locoregional radiotherapy. Is this a problem and, if so, to what extent?